Table 3 The diagnostic performance of tRF-23-Q99P9P9NDD, CEA, CA199 and CA724 in differentiating GC patients from healthy donors
| Â | SEN (%) | SPE (%) | ACCU (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
tRF-23-Q99P9P9NDD | 0.67 (83/124) | 0.86 (102/119) | 0.76 (185/243) | 0.83 (83/100) | 0.71 (102/143) |
CEA | 0.60 (74/124) | 0.74 (88/119) | 0.67 (162/243) | 0.70 (74/105) | 0.64 (88/138) |
CA199 | 0.44 (55/124) | 0.77 (92/119) | 0.60 (147/243) | 0.67 (55/82) | 0.57 (92/161) |
CA724 | 0.53 (66/124) | 0.86 (102/119) | 0.69 (168/243) | 0.80 (66/83) | 0.64 (102/160) |
tRF-23-Q99P9P9NDD + CEA | 0.71 (88/124) | 0.65 (77/119) | 0.68 (165/243) | 0.68 (88/130) | 0.68 (77/113) |
tRF-23-Q99P9P9NDD + CA199 | 0.73 (90/124) | 0.73 (87/119) | 0.73 (177/243) | 0.74 (90/122) | 0.72 (87/121) |
tRF-23-Q99P9P9NDD + CA724 | 0.80 (99/124) | 0.76 (90/119) | 0.78 (189/243) | 0.77 (99/128) | 0.78 (90/115) |
tRF-23-Q99P9P9NDD + CEA + CA199 | 0.75 (93/124) | 0.56 (67/119) | 0.66 (160/243) | 0.64 (93/145) | 0.68 (67/98) |
tRF-23-Q99P9P9NDD + CEA + CA724 | 0.81 (101/124) | 0.56 (67/119) | 0.69 (168/243) | 0.66 (101/153) | 0.74 (67/90) |
tRF-23-Q99P9P9NDD + CEA + CA199 + CA724 | 0.83 (103/124) | 0.49 (58/119) | 0.66 (161/243) | 0.63 (103/164) | 0.73 (58/79) |